AtaiBeckley Inc. - Common Stock (ATAI)

4.9000
+0.8700 (21.59%)
NASDAQ · Last Trade: Apr 20th, 9:18 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
This 4/20, Wall Street Is Betting on More Than Marijuanamarketbeat.com
Via MarketBeat · April 20, 2026
AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Ratingbenzinga.com
AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews.
Via Benzinga · April 20, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · April 20, 2026
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soarfool.com
Trump is easing approval for psychedelic treatments for mental disorders.
Via The Motley Fool · April 20, 2026
These stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 20, 2026
Top movers in Monday's pre-market sessionchartmill.com
Via Chartmill · April 20, 2026
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more radical, rapid-acting interventions. At the forefront of this neuro-psychiatric revolution stands GH Research PLC (Nasdaq: GHRS), a Dublin-based biopharmaceutical firm that has just crossed a critical threshold [...]
Via Finterra · March 26, 2026
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026marketbeat.com
Via MarketBeat · January 19, 2026
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatmentstocktwits.com
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.
Via Stocktwits · January 5, 2026
MarketBeat’s Top 5 Rated Small-Cap Stocksmarketbeat.com
Via MarketBeat · December 22, 2025
Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Orderstocktwits.com
Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.
Via Stocktwits · December 19, 2025
Analyst Expectations For ATAI Life Sciences's Futurebenzinga.com
Via Benzinga · October 22, 2025
Why Atai Life Sciences Stock Was So Lively This Weekfool.com
The company, which focuses on psychedelic-based medicine, had a busy few days on both the regulatory and financing fronts.
Via The Motley Fool · October 17, 2025
Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides
As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This significant market event underscores a nuanced financial landscape where both defensive stability and high-growth innovation are being richly rewarded. The surge in valuations
Via MarketMinute · October 14, 2025
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upsidebenzinga.com
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035.
Via Benzinga · October 13, 2025
Alibaba, Lithium Americas And Other Big Stocks Moving Higher In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 24, 2025
Why Atai Life Sciences Stock Crushed It on Tuesdayfool.com
Investors cheered good news from the lab delivered by the company.
Via The Motley Fool · September 23, 2025
Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviewsbenzinga.com
Via Benzinga · September 23, 2025
Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patientsbenzinga.com
Atai Life Sciences and Beckley Psytech report strong BPL-003 study results in treatment-resistant depression, with Phase 3 trials expected in 2026.
Via Benzinga · September 23, 2025
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%benzinga.com
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA),
Via Benzinga · September 18, 2025
Atai Life Sciences Revenue Jumps 163%fool.com
Via The Motley Fool · August 14, 2025
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Via Benzinga · July 30, 2025
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesdaybenzinga.com
Via Benzinga · July 29, 2025
Why Is ATAI Life Sciences Stock Trading Lower On Monday?benzinga.com
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile.
Via Benzinga · July 28, 2025
What's going on in today's pre-market sessionchartmill.com
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Via Chartmill · July 28, 2025